Dominick C. Colangelo has been leading Vericel Corporation as President and CEO since March 2013. With an MBA from Harvard Business School, he brings strong business acumen to the biotechnology sector. Under his leadership, Vericel has made significant strides, focusing...
Dominick C. Colangelo has been leading Vericel Corporation as President and CEO since March 2013. With an MBA from Harvard Business School, he brings strong business acumen to the biotechnology sector. Under his leadership, Vericel has made significant strides, focusing on innovative cell therapy products. For instance, he successfully navigated the company to surpass key revenue targets and achieve a remarkable total shareholder return of 219% in 2018. Interestingly, his annual compensation reflected the company's performance, with a major boost in 2018 tied to a strong achievement of corporate goals. Notably, as part of his employment agreement, he was granted stock options to align his interests with the company's growth. This means he's not just leading from the front, but also has financial skin in the game. His ability to attract investment and expand product offerings has been crucial for Vericel's success in a competitive landscape.